The Impact of Liquid Biopsies Positive for <em>EGFR</em> Mutations on Overall Survival in Non-Small Cell Lung Cancer Patients
Jonnathan Roldan Ruiz,
Marta Gracia Fuentes Gago,
Luis Miguel Chinchilla Tabora,
Idalia Gonzalez Morais,
José María Sayagués,
Mar Abad Hernández,
Maria Rosa Cordovilla Pérez,
Maria Dolores Ludeña de la Cruz,
Edel del Barco Morillo,
Marta Rodriguez Gonzalez
Affiliations
Jonnathan Roldan Ruiz
Department of Clinical Oncology, Biomedical Research Institute of Salamanca (IBSAL), University Hospital of Salamanca, University of Salamanca, 37007 Salamanca, Spain
Marta Gracia Fuentes Gago
Department of Thoracic Surgery, University Hospital of Salamanca, 37007 Salamanca, Spain
Luis Miguel Chinchilla Tabora
Department of Pathology, Biomedical Research Institute of Salamanca (IBSAL), University Hospital of Salamanca, 37007 Salamanca, Spain
Idalia Gonzalez Morais
Department of Pathology, Biomedical Research Institute of Salamanca (IBSAL), University Hospital of Salamanca, 37007 Salamanca, Spain
José María Sayagués
Department of Pathology, Biomedical Research Institute of Salamanca (IBSAL), University Hospital of Salamanca, 37007 Salamanca, Spain
Mar Abad Hernández
Department of Pathology, Biomedical Research Institute of Salamanca (IBSAL), University Hospital of Salamanca, 37007 Salamanca, Spain
Maria Rosa Cordovilla Pérez
Department of Pulmonology, University Hospital of Salamanca, 37007 Salamanca, Spain
Maria Dolores Ludeña de la Cruz
Department of Pathology, Biomedical Research Institute of Salamanca (IBSAL), University Hospital of Salamanca, 37007 Salamanca, Spain
Edel del Barco Morillo
Department of Clinical Oncology, Biomedical Research Institute of Salamanca (IBSAL), University Hospital of Salamanca, University of Salamanca, 37007 Salamanca, Spain
Marta Rodriguez Gonzalez
Department of Pathology, Biomedical Research Institute of Salamanca (IBSAL), University Hospital of Salamanca, 37007 Salamanca, Spain
In recent years, non-small cell lung cancer treatment has been revolutionized. EGFR tyrosine kinase inhibitors and our improved understanding of its alterations have driven new diagnostic strategies. Liquid biopsies have emerged as a useful tool in these contexts, showing potential utility in early diagnosis combined with low-dose CT scans, as well as potential in monitoring treatment response and predicting the development of patients. We studied the circulating tumor DNA (ctDNA) of 38 EGFR-mutated non-small cell lung cancer patients at diagnosis in different moments of their disease by liquid biopsy techniques. Our results show that mean overall survival was significantly lower when a liquid biopsy was positive for the detection of EGFR mutations compared with wild-type patients in their liquid biopsy in both univariate (29 ± 4 vs. 104 ± 19 months; p = 0.004) and multivariate analysis (p = 0.008). Taking this into consideration, liquid biopsies could be key to improving the control of this disease.
